Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2013

View Archived Issues

Proof-of-concept demonstration of functional regeneration via stem-cell organ bud transplantation

to-BBB Holding presents promising phase I results for new oncolytic agent

Novel furin inhibitors patented

Axikin presents novel MAP3K19 inhibitors

Bayer discloses new TTK inhibitors for cancer

Lupin reports novel MEK inhibitors

Isis Pharmaceuticals reaches milestone in phase II study in spinal muscular atrophy

Synergy Pharmaceuticals begins phase II study of SP-333

KB-3944, a promising new drug for multiple sclerosis

Puma Biotechnology begins phase II trial of PB-272 in HER2 solid tumors

PharmAkea Therapeutics and Celgene to advance therapies for cancer and fibrotic disease

Targeting LINGO1, a promising therapeutic strategy for multiple sclerosis

Phase Ib/II study of Erivedge begins in relapsed/refractory AML and high-risk MDS

MRC Technology and Renishaw Diagnostics collaborate on diagnostics for infectious disease

MJFF grant supports Durin Technologies' blood test for Parkinson's disease

European submission to broaden label for Arzerra to include first-line CLL

Cognoptix demonstrates potential of Sapphire II eye test to identify patients with Alzheimer's

Astellas and Mitokyne establish R&D collaboration for mitochondria-related disorders

ETC and Debiopharm establish oncology research collaboration

PeptiDream and Ipsen expand collaboration

MorphoSys completes phase I/IIa study of MOR-208 in CLL

Amplimmune acquisition strengthens MedImmune's oncology pipeline

Safety and efficacy of INCB-039110 confirmed in patients with psoriasis

Axiron testosterone replacement therapy approved in Germany

Researchers present phase I results for the anti-IL-31 receptor antibody CIM-331

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...